Trv Gp Iv LLC Acquires New Position in Maze Therapeutics, Inc. $MAZE

Trv Gp Iv LLC purchased a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 4,473,958 shares of the company's stock, valued at approximately $133,502,907. Maze Therapeutics makes up approximately 0.1% of Trv Gp Iv LLC's investment portfolio, making the stock its biggest position. Trv Gp Iv LLC owned 8.08% of Maze Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. Royal Bank of Canada boosted its holdings in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company's stock valued at $27,000 after acquiring an additional 363 shares during the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock valued at $42,000 after buying an additional 738 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in shares of Maze Therapeutics during the 4th quarter valued at approximately $43,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Maze Therapeutics in the second quarter worth approximately $48,000. Finally, Russell Investments Group Ltd. grew its position in Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company's stock valued at $49,000 after purchasing an additional 1,725 shares in the last quarter.

Insider Transactions at Maze Therapeutics

In other Maze Therapeutics news, CMO Harold Bernstein sold 16,142 shares of the company's stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $27.61, for a total transaction of $445,680.62. Following the completion of the sale, the chief marketing officer owned 16,142 shares in the company, valued at $445,680.62. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the business's stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $29.98, for a total value of $1,034,339.98. Following the sale, the chief executive officer owned 23,337 shares of the company's stock, valued at approximately $699,643.26. This trade represents a 59.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 108,110 shares of company stock valued at $3,057,531. 5.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts recently commented on MAZE shares. Weiss Ratings restated a "sell (d-)" rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. TD Cowen upgraded shares of Maze Therapeutics to a "strong-buy" rating in a research report on Monday. BTIG Research reiterated a "buy" rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Finally, Wall Street Zen downgraded shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Three investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $66.00.

Maze Therapeutics Stock Performance

MAZE traded down $1.18 during trading hours on Friday, hitting $27.42. The company's stock had a trading volume of 79,738 shares, compared to its average volume of 643,743. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $1.52 billion, a PE ratio of -10.88 and a beta of 2.21. Maze Therapeutics, Inc. has a fifty-two week low of $13.89 and a fifty-two week high of $53.65. The company has a 50-day simple moving average of $28.70 and a 200 day simple moving average of $31.93.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.76). As a group, sell-side analysts expect that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

About Maze Therapeutics

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.